Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 3/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 4/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | UGT1A4 | P22310 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11044204 | 0.92 | KIF11 (0.52) | KIF11ESR1ESR2RORCTSHR | |
| SCHEMBL307338 | 0.89 | TSHR (0.52) | KIF11ESR1ESR2RORCSCN10A | |
| SCHEMBL3413029 | 0.87 | MEN1 (0.50) | KIF11ESR1ESR2RORCCYP19A1 | |
| SCHEMBL306585 | 0.87 | KIF11 (0.59) | KIF11CYP19A1TSHRALDH1A1 | |
| SCHEMBL13578 | 0.87 | CYP2A6 (0.38) | KIF11ESR1ESR2RORCSCN10A | |
| SCHEMBL1244431 | 0.87 | ESR1 (0.55) | ESR1ESR2MTORCYP19A1TSHR | |
| SCHEMBL358617 | 0.87 | MAPT (0.43) | KIF11ESR1ESR2RORCSCN10A | |
| SCHEMBL7383205 | 0.87 | KIF11 (0.34) | KIF11ESR1ESR2RORCSCN10A | |
| SCHEMBL11055 | 0.87 | APP (0.36) | KIF11ESR1ESR2RORCSCN10A | |
| SCHEMBL2534039 | 0.87 | RAB9A (0.37) | KIF11ESR1ESR2RORCSCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144225-A1 | METHOD FOR TREATING SURFACES | BASF SE (DE) | 2010-06-10 | — | — | US | disclosed |
| EP-1296945-B1 | SULFONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2004-08-04 | — | — | EP | disclosed |
| US-6703425-B2 | ADMINISTERING GLUTAMATE RECEPTOR POTENTIATOR TO TREAT PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY | 2004-03-09 | — | — | US | disclosed |
| US-20030229102-A1 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
| EP-1296945-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001096289-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| EP-0349195-B1 | Direct synthesis by cationic polymerization of nitrogen-containing polymers | EXXON CHEMICAL PATENTS INC (US) | 1997-05-21 | — | — | EP | disclosed |
| US-5629394-A | ENDCAPPING ADDITION POLYMERS WITH NITROGEN FUNCTIONAL GROUPS WHICH CAN BE FURTHER DERIVATIZED | EXXON CHEMICAL PATENTS INC (US) | 1997-05-13 | — | — | US | disclosed |
| US-5444135-A | Polymerization and functionalization with nitrogen-containing functional groups occur simultaneously | EXXON CHEMICAL PATENTS INC. (US) | 1995-08-22 | — | — | US | disclosed |
| US-5032653-A | Catalysts | EXXON CHEMICAL PATENTS, INC. (US) | 1991-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229102-A1 | Sulfonamide derivatives | GRIN1, GRIN2A, SLC1A2 | KIF11 3122/4885ESR1 3585/4885ESR2 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.